used to falsely represent Respondent's own experiment for bone nodules formed in osteoblastic niche cells from young and aged mice.

• Respondent falsely represented eight (8) flow cytometry contour plots as different experimental results by using identical plots but with different labels and different numerical percentages. Specifically, the following contour plots in the *Blood* paper, the *Nature* paper, an earlier version of the *Nature* paper submitted to *Science* (hereafter referred to as the ''*Science* manuscript''), and a July 2008 PowerPoint presentation were identical but were labeled differently:

a. Panels 4 and 2 in Figure 6C, *Blood* paper, and panels 1 and 2, respectively, in supplementary Figure 3b, *Nature* paper
b. Panel 3 in Figure 6C, *Blood* paper, and panel 1 in Figure 2, July 2008 PowerPoint presentation
c. Panels 1 and 2, Figure 2b, *Science* manuscript, and panels 2 and 3, respectively, in Figure 2, July 2008 PowerPoint presentation
d. Panels 2, 3, and 4, supplemental Figure 4A, *Blood* paper, and panels 3, 1, and 2, respectively, in Figure 4B, *Science* manuscript

Both the Respondent and HHS want to conclude this matter without further expenditure of time or other resources and have entered into a Voluntary Settlement Agreement to resolve this matter. Respondent neither admits nor denies ORI's finding of research misconduct. This settlement does not constitute an admission of liability on the part of the Respondent. Dr. Mayack has voluntarily agreed:

(1) If within three (3) years from the effective date of the Agreement, Respondent does receive or apply for U.S. Public Health Service (PHS) support, Respondent agrees to have her research supervised for a period of three (3) years beginning on the date of her employment in a research position in which she receives or applies for PHS support and to notify her employer(s)/institution(s) of the terms of this supervision; Respondent agrees that prior to the submission of an application for PHS support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent's duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agrees that she shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agrees to maintain responsibility for compliance with the agreed upon supervision plan;

(2) If within three (3) years from the effective date of the Agreement, Respondent does receive or apply for PHS support, Respondent agrees that any institution employing her shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and

(3) To exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on July 27, 2012.

**FOR FURTHER INFORMATION CONTACT:** Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

**John Dahlberg,**

*Director, Division of Investigative Oversight, Office of Research Integrity.*

[FR Doc. 2012–21236 Filed 8–27–12; 8:45 am]

**BILLING CODE 4150–31–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

**[Document Identifier: CMS–10003]**

### Public Information Collection Requirements Submitted to the Office of Management and Budget (OMB); Correction

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), HHS.

**ACTION:** Correction of notice.

**SUMMARY:** This document corrects a technical error in the notice [Document Identifier: CMS–10003] entitled ''Notice of Denial of Medical Coverage (or Payment)'' that was published in the July 6, 2012 (77 FR 40064) **Federal Register**.

**FOR FURTHER INFORMATION CONTACT:** William Parham, (410) 786–4669.

**SUPPLEMENTARY INFORMATION:**

**I. Background**

In the FR Doc. 2012–16514 of July 6, 2012 (77 FR 40064), we published a Paperwork Reduction Act notice requesting a 60-day public comment period for the document entitled ''Notice of Denial of Medical Coverage (or Payment).''

In the July 6, 2012 notice, we listed the incorrect contact information. Therefore, we are correcting that error in this notice.

**II. Correction of Error**

In FR Doc. 2012–16514 of July 6, 2012 (77 FR 40064), make the following correction:

On page 40068, first column, fourth full paragraph, on the fifteenth line in the paragraph beginning with ''(For policy questions regarding, '' and ending with, ''410–786–0273),'' is corrected to read as follows.

''(For policy questions regarding this collection contact Kathryn McCann Smith at 410–786–7623.)''

Dated: August 22, 2012.

**Martique Jones,**

*Director, Regulations Development Group, Division B, Office of Strategic Operations and Regulatory Affairs.*

[FR Doc. 2012–21076 Filed 8–23–12; 11:15 am]

**BILLING CODE 4120–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2008–E–0102]**

### Determination of Regulatory Review Period for Purposes of Patent Extension; TORISEL

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined the regulatory review period for TORISEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

**ADDRESSES:** Submit electronic comments to *http://www.regulations.gov.* Submit written petitions along with three copies and written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.